Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States.

ABSTRACT:

Background

Chronic hepatitis D virus (HDV) infection increases the risk of liver-related deaths in adults with chronic hepatitis B (CHB). In the United States (US), only an estimated 12.9% of adults with CHB have received an HDV antibody test. The aim of this study is to calculate the cost-effectiveness of one-time universal HDV testing of hepatitis B surface antigen (HBsAg)-positive adults living in the US.

Methods

A Markov model was used to calculate the costs, health impact, and cost-effectiveness of universal testing of HBsAg-positive adults with an HDV antibody test and, when positive, an HDV RNA test for chronic HDV infection. We assumed that 50% of the HDV RNA-positive patients would receive the current recommended treatment with pegylated interferon (PEG-IFN) for 48

SUBMITTER: Toy M 

PROVIDER: S-EPMC12598672 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature